Updates on Financial Results and Stock Price Movements - Research Report on Regeneron, Covidien, Salix Pharmaceuticals, Celldex Therapeutics, and Capital Senior Living
NEW YORK, November 8, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Covidien plc (NYSE: COV), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), Celldex Therapeutics, Inc. (NASDAQ: CLDX), and Capital Senior Living Corporation (NYSE: CSU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Regeneron Pharmaceuticals Inc. Research Report
On November 5, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) reported its Q3 2013 financial results. The Company's revenues increased 39.6% YoY to $597.0 million during the quarter. Net income was $141.3 million or $1.25 per diluted share in Q3 2013, compared to net income of $191.5 million or $1.72 per diluted share in Q3 2012. Commenting on the results, Leonard S. Schleifer, M.D., Ph.D., President and CEO of Regeneron, said, "We are pleased with our quarterly financial performance, which continues to be driven by both the U.S. and ex-U.S. growth of EYLEA. Moreover, our late stage clinical pipeline continues to have strong momentum. Importantly, today we announced that we recently submitted to the FDA a supplemental BLA in the diabetic macular edema (DME) indication, and are encouraged that we were able to accomplish this approximately one-year ahead of our original plan. In the third quarter, we previously reported positive Phase 3 data for EYLEA in DME. We also announced two additional positive Phase 3 trials last month - the VIBRANT trial for EYLEA in macular edema following branch retinal vein occlusion (BRVO) and the ODYSSEY MONO trial for alirocumab in patients with elevated cholesterol." Schleifer added, "Finally, we expect to report results from the Phase 3 MOBILITY trial for sarilumab in patients with rheumatoid arthritis before the end of the year." The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8ea7_REGN]
Covidien plc Research Report
On November 5, 2013, Covidien plc's (Covidien) stock declined 0.49%, ending the day at $64.33. Over the previous three trading sessions, the shares of Covidien gained 0.34% compared to the S&P 500 which gained 0.37% during the same period. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/a14c_COV]
Salix Pharmaceuticals, Ltd. Research Report
On November 5, 2013, Salix Pharmaceuticals Ltd.'s (Salix Pharmaceuticals) stock rose 1.10%, ending the day at $74.56. Over the previous three trading sessions, shares of Salix Pharmaceuticals gained 3.92%, outperforming the Nasdaq Composite which gained 0.51% during the same period. The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/04fa_SLXP]
Celldex Therapeutics, Inc. Research Report
On November 5, 2013, Celldex Therapeutics, Inc.'s (Celldex Therapeutics) stock declined 0.51%, ending the day at $23.43. Over the previous three trading sessions, shares of Celldex Therapeutics gained 2.31%, outperforming the Nasdaq Composite which gained 0.51% during the same period. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b443_CLDX]
Capital Senior Living Corporation Research Report
On November 4, 2013, Capital Senior Living Corporation (Capital Senior Living) reported its Q3 2013 financial results. The Company's total revenues increased 12.8% YoY to $88.0 million during the quarter. Net loss was $10.0 million or $0.35 per diluted share in Q3 2013, compared to net loss of $937,000 or $0.03 per diluted share in Q3 2012. Commenting on the results, Lawrence A. Cohen, CEO of Capital Senior Living, said, "Same store occupancy at the end of September was 70 basis points higher than occupancy at the end of June. This significant increase, along with a 20% increase in third quarter deposits, bodes well for fourth quarter financial results." Cohen added, "We are also pleased to report that a re-positioning of our two continuing care retirement communities to further enhance our private-pay revenues is proceeding well. After considering a number of alternatives, including a sale of these owned communities, we decided that a reconfiguration of the services we offer will enhance annual CFFO, improve our operating metrics and enable meaningful gains in shareholder value. The residents we served in skilled nursing have nearly all been relocated to other nursing homes and we will soon begin reconfiguring this space for private-pay use." The Full Research Report on Capital Senior Living Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ca95_CSU]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystscorner.com/
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article